Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Sanofi (SNY): Dupixent Momentum, Rare Disease Strength & Blueprint Acquisition—What’s the Impact, Valuation Outlook & its 5 Key Catalysts?
Sanofi entered FY25 with accelerating operational momentum, posting 9.7% constant-currency sales growth to €9.9B and 15.7% EPS growth, driven by Dupixent’s 20% YoY gain to €3.5B and strength in new launches like ALTUVIIIO and Beyfortus. Dupixent’s rapid expansion, now supported by 90% Medicare and 88% commercial COPD coverage, along with growing international traction, solidifies its path to €22B by 2030. Gross margin expanded 230bps to 78%, reflecting portfolio mix shift and manufacturing efficiencies, with further margin tailwinds likely as novel modalities scale. The Qfitlia launch, robust Beyfortus demand, and a €1.1B revenue contribution from new products validate strategic rotation toward innovation. The €10B CHC spin proceeds support pipeline reinvestment and M&A (e.g., Blueprint’s Ayvakit and elenestinib), while the €5B buyback program (76% executed) mitigates dilution. Blueprint adds depth to rare disease and immunology, with Ayvakit targeting $2B peak sales and BLU-808/Elenestinib adding pipeline breadth. A dense 2025 catalyst calendar includes 11 Phase III readouts and 15+ regulatory actions, with key data from itepekimab, tolebrutinib, and amlitelimab poised to reshape Sanofi’s immunology franchise. With margin upside, blockbuster pipeline optionality, and strategic capital allocation, Sanofi’s immunology-led model remains well supported—but can it maintain clinical differentiation and Dupixent’s trajectory amid mounting biologics competition and pipeline execution risk?
